| Market Cap | 80.70M | P/E | - | EPS this Y | 58.50% | Ern Qtrly Grth | - |
| Income | -10.08M | Forward P/E | -1.85 | EPS next Y | 5.90% | 50D Avg Chg | -3.00% |
| Sales | 54.23M | PEG | -0.07 | EPS past 5Y | - | 200D Avg Chg | -10.00% |
| Dividend | N/A | Price/Book | 1.24 | EPS next 5Y | 36.90% | 52W High Chg | -52.00% |
| Recommedations | 2.20 | Quick Ratio | 4.61 | Shares Outstanding | 52.72M | 52W Low Chg | 116.00% |
| Insider Own | 18.94% | ROA | -10.19% | Shares Float | 36.87M | Beta | 0.89 |
| Inst Own | 27.24% | ROE | -22.24% | Shares Shorted/Prior | 1.14M/1.17M | Price | 1.54 |
| Gross Margin | 24.51% | Profit Margin | -18.59% | Avg. Volume | 312,087 | Target Price | 6.67 |
| Oper. Margin | -24.42% | Earnings Date | Nov 13 | Volume | 258,744 | Change | 0.99% |
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, a novel oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
| HC Wainwright & Co. | Buy | Sep 5, 23 |
| HC Wainwright & Co. | Buy | Aug 14, 23 |
| HC Wainwright & Co. | Buy | Aug 1, 23 |
| HC Wainwright & Co. | Buy | Jul 20, 23 |
| HC Wainwright & Co. | Buy | Apr 10, 23 |
| HC Wainwright & Co. | Buy | Sep 26, 22 |
| Evercore ISI Group | Outperform | Sep 23, 22 |
| HC Wainwright & Co. | Buy | Aug 15, 22 |
| HC Wainwright & Co. | Buy | May 23, 22 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| HAMED KAMAL | Chief Medical Office.. Chief Medical Officer | Sep 13 | Sell | 1.27 | 39,496 | 50,160 | 576,461 | 09/15/23 |
| Keutzer Timothy | Chief Operating Offi.. Chief Operating Officer | Feb 01 | Sell | 1.86 | 3,394 | 6,313 | 327,144 | 02/03/23 |
| JOSEPH TAMARA L | Chief Legal Officer Chief Legal Officer | Feb 01 | Sell | 1.86 | 3,394 | 6,313 | 324,644 | 02/03/23 |
| Shukla Sath | Chief Financial Offi.. Chief Financial Officer | Feb 01 | Sell | 1.83 | 9,504 | 17,392 | 312,517 | 02/03/23 |
| Shukla Sath | Chief Financial Offi.. Chief Financial Officer | Aug 29 | Sell | 0.8938 | 6,017 | 5,378 | 56,064 | 08/30/22 |
| Aquilo Capital Management, LLC | 10% Owner 10% Owner | Feb 18 | Buy | 9.2419 | 14,828 | 137,039 | 5,162,963 | 02/23/22 |
| Aquilo Capital Management, LLC | 10% Owner 10% Owner | Jan 31 | Buy | 11.5861 | 125,000 | 1,448,262 | 5,148,135 | 02/01/22 |
| Aquilo Capital Management, LLC | 10% Owner 10% Owner | Jan 24 | Buy | 10.8931 | 1,599 | 17,418 | 5,023,135 | 01/26/22 |
| Aquilo Capital Management, LLC | 10% Owner 10% Owner | Jan 18 | Buy | 12.4147 | 48,488 | 601,964 | 5,021,536 | 01/20/22 |
| Aquilo Capital Management, LLC | 10% Owner 10% Owner | Jan 10 | Buy | 12.9253 | 8,867 | 114,609 | 4,973,048 | 01/12/22 |
| Mahadevia Ankit | CEO and President CEO and President | Dec 27 | Option | 5.9 | 8,000 | 47,200 | 152,036 | 12/29/21 |
| Mahadevia Ankit | CEO and President CEO and President | Dec 27 | Sell | 14.58 | 8,000 | 116,640 | 144,036 | 12/29/21 |
| Aquilo Capital Management, LLC | 10% Owner 10% Owner | Sep 15 | Buy | 18.53 | 46,366 | 859,162 | 4,429,145 | 09/15/21 |
| Aquilo Capital Management, LLC | 10% Owner 10% Owner | Aug 27 | Buy | 16.71 | 36,939 | 617,251 | 4,265,343 | 08/27/21 |
| - | - - | Feb 04 | Sell | 19.05 | 100,000 | 1,905,000 | 3,832,209 | 02/04/21 |
| - | - - | Dec 18 | Sell | 18.72 | 264,933 | 4,959,546 | 3,932,209 | 12/18/20 |
| - | - - | Nov 06 | Sell | 14 | 174,100 | 2,437,400 | 4,323,042 | 11/06/20 |
| Mahadevia Ankit | CEO and President CEO and President | Nov 05 | Option | 5.9 | 9,507 | 56,091 | 73,187 | 11/05/20 |
| Mahadevia Ankit | CEO and President CEO and President | Nov 05 | Sell | 14.35 | 9,507 | 136,425 | 65,817 | 11/05/20 |
| Mahadevia Ankit | CEO and President CEO and President | Oct 27 | Option | 5.9 | 20 | 118 | 65,837 | 10/27/20 |
| Mahadevia Ankit | CEO and President CEO and President | Oct 27 | Sell | 14.25 | 20 | 285 | 65,817 | 10/27/20 |
| Mahadevia Ankit | CEO and President CEO and President | Oct 15 | Option | 5.9 | 14,472 | 85,385 | 65,922 | 10/15/20 |
| Mahadevia Ankit | CEO and President CEO and President | Oct 15 | Sell | 14.27 | 14,472 | 206,515 | 65,817 | 10/15/20 |
| Mahadevia Ankit | CEO and President CEO and President | Sep 10 | Sell | 14.25 | 774 | 11,030 | 65,817 | 09/10/20 |
| Mahadevia Ankit | CEO and President CEO and President | Sep 10 | Option | 5.9 | 774 | 4,567 | 66,591 | 09/10/20 |